Detection of a tumor‐associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1‐40F4) in enzyme immunoassay

The urine of 68% of melanoma patients contains a high molecular weight glycoprotein which is expressed by melanoma cells and reacts with autologous antibody. Since high levels of this antigen in urine correlate with disease recurrence in surgically treated melanoma patients, it has been termed urinary tumor‐associated antigen (U‐TAA). We report the development of a murine monoclonal IgM antibody (AD1‐40F4), which is specific for U‐TAA. AD1‐40F4 showed the same pattern of reactivity as the allo‐antibodies previously used for the detection of U‐TAA. The antigen recognized by AD1‐40F4 has a high molecular weight (590– 620 kilodaltons [kd]) and is heat stable. The AD1‐40F4‐reactive epitope is a protein. When AD1‐40F4 was applied in an enzyme immunoassay, it allowed for the detection of U‐TAA in the serum of 64% (33/52) of melanoma patients as opposed to only 5% (1/20) of normal controls. Thus, the murine monoclonal antibody AD1‐40F4, which has been specifically developed against an allogeneic antibody defined antigen, U‐TAA, appears to be important for immuno‐prognosis of human melanoma.